February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.

Researchers from Ohio State University, led by Distinguished Professor John J. Coccyx and graduate student Arshad Ahmad from Heritage College of Osteopathic Medicine have discovered a potential new ...

Lung cancer remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for a nuanced ...

Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics.

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

The global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035 ...

Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...

SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments ...

Dr. Jay Miller, a pulmonary critical care physician from New Orleans, is stranded in Doha after his flight home was forced to ...